Ieq Capital LLC Acquires 145 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Ieq Capital LLC raised its stake in Inari Medical, Inc. (NASDAQ:NARI) by 0.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,198 shares of the company’s stock after buying an additional 145 shares during the quarter. Ieq Capital LLC owned about 0.09% of Inari Medical worth $2,563,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NARI. Aigen Investment Management LP bought a new position in shares of Inari Medical during the third quarter worth about $428,000. Vestal Point Capital LP boosted its position in Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after acquiring an additional 1,200,000 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Inari Medical in the third quarter valued at approximately $1,397,000. Verition Fund Management LLC acquired a new stake in shares of Inari Medical in the third quarter valued at approximately $1,235,000. Finally, Jane Street Group LLC lifted its position in shares of Inari Medical by 32.4% in the third quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock worth $3,927,000 after purchasing an additional 23,286 shares in the last quarter. Institutional investors own 90.98% of the company’s stock.

Insider Transactions at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the sale, the director now directly owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 263,000 shares of company stock worth $15,599,470. 10.60% of the stock is owned by insiders.

Inari Medical Price Performance

Shares of Inari Medical stock opened at $79.97 on Friday. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.99. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The business has a fifty day simple moving average of $71.49 and a two-hundred day simple moving average of $55.47.

Analysts Set New Price Targets

Several brokerages have issued reports on NARI. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Baird R W downgraded Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Canaccord Genuity Group reissued a “hold” rating and set a $80.00 price target (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $80.00 price target (up previously from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $68.00.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.